Education
About Us
Working with TipRanks
Follow Us
Applied Uv, Inc. (AUVIQ)
OTHER OTC:AUVIQ
Top Page
Applied UV
(OTC:AUVIQ)
Rating:41Neutral
Price Target:―
Applied UV (AUVIQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$467.00
Dividend YieldN/A
Average Volume (3M)1.27K
Price to Earnings (P/E)―
Beta (1Y)3.81
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees131
SectorConsumer Cyclical
Sector Strength81
IndustryFurnishings, Fixtures & Appliances
Share Statistics
EPS (TTM)-64.65
Shares Outstanding4,674,495
10 Day Avg. Volume1,275
30 Day Avg. Volume1,275
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Applied UV Business Overview & Revenue Model
Company DescriptionApplied UV (AUVIQ) is a technology company focused on the development and commercialization of advanced disinfection solutions. The company operates primarily in the healthcare, hospitality, and food preservation sectors. Its core products include patented ultraviolet (UV) technology systems designed to eliminate pathogens and improve air quality, thereby enhancing sanitation standards across various environments.
How the Company Makes MoneyApplied UV generates revenue primarily through the sale of its UV disinfection systems and related services. The company's key revenue streams include direct sales to healthcare facilities, hotels, food processing plants, and other commercial entities looking to enhance their sanitation protocols. Additionally, Applied UV may establish partnerships with distributors and service providers to expand its market reach. The company may also earn income from maintenance and support services associated with its products, as well as potential licensing agreements for its patented technology.
Applied UV Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.72M | 20.14M | 11.67M | 5.73M | 9.33M |
| Gross Profit | 7.83M | 4.04M | 4.10M | 1.01M | 3.32M |
| EBITDA | -9.05M | -8.87M | -5.71M | -3.30M | 1.41M |
| Net Income | -13.20M | -22.05M | -7.39M | -3.37M | 2.80M |
Balance Sheet | |||||
| Total Assets | 58.39M | 32.73M | 38.53M | 13.12M | 4.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 2.73M | 7.92M | 11.76M | 1.03M |
| Total Debt | 8.21M | 7.77M | 1.90M | 950.64K | 793.61K |
| Total Liabilities | 33.50M | 15.49M | 5.86M | 3.36M | 3.38M |
| Stockholders Equity | 24.88M | 17.23M | 32.67M | 9.75M | 1.38M |
Cash Flow | |||||
| Free Cash Flow | -8.78M | -8.76M | -7.03M | -875.86K | 757.26K |
| Operating Cash Flow | -8.22M | -8.74M | -7.00M | -657.23K | 770.26K |
| Investing Cash Flow | -4.84M | -176.28K | -14.59M | -218.63K | -13.00K |
| Financing Cash Flow | 11.46M | 2.88M | 18.60M | 11.60M | -521.09K |
Applied UV Risk Analysis
Applied UV disclosed 85 risk factors in its most recent earnings report. Applied UV reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Applied UV Peers Comparison
Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.02B | 12.77 | -0.74% | 3.01% | 1.30% | -13.03% | |
58 Neutral | $30.85M | ― | -46.19% | ― | 19.03% | 11.70% | |
42 Neutral | $3.00M | ― | -130.75% | ― | -2.96% | 89.71% | |
41 Neutral | $467.00 | ― | -53.06% | ― | ― | ― | |
38 Underperform | $1.75M | ― | -207.29% | ― | ― | 78.72% | |
38 Underperform | $3.70M | ― | -240.46% | ― | -50.14% | 81.11% | |
32 Underperform | $6.23M | ― | -253.29% | ― | 415.58% | 90.81% |
* Consumer Cyclical Sector Average
Performance Comparison
AUVIQ
Applied UV
0.01
0.00
0.00%
CLIR
ClearSign Combustion
0.58
-0.23
-28.40%
APDN
Applied DNA Sciences
2.39
-1,130.11
-99.79%
AEMD
Aethlon Medical
0.65
-2.37
-78.48%
SGBX
Sg Blocks
7.48
-56.51
-88.31%
ENSC
Ensysce Biosciences
2.12
-2.90
-57.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.